CORDIS
EU research results

CORDIS

English EN

Consortium for Research into Nuclear Receptors in Development and Aging

Objective

Nuclear receptors function throughout development and aging as molecular integrators of complex physiological regulations, such as growth, reproduction and metabolism. To translate genetic knowledge from the Human Genome into therapy requires intimate understanding of fundamental regulatory mechanisms. CRESCENDO will build on existing knowledge and infrastructures by drawing together European excellence to focus on signalling dynamics, integration of target gene responses during development and aging, and human genetics and pathophysiology, emphasising key nuclear receptors. State-of-the-art genomic and post-genomic techniques will lever advances on mechanisms and kinetics of nuclear receptor signalling in processes underlying development and aging. Information on spatial and temporal aspects of signalling dynamics will feed into a broader vision of how nuclear receptors integrate multiple inputs in whole organisms across the life span. Focus will be on developmental targets, on brain development and aging, and the complex interplay between metabolism, particularly glucose and lipid signalling, and brain function. The brain is emphasised, as its disorders often cause most distress in unhealthy aging. A strong investment in bioinformatics will facilitate data extraction from multi-level analyses (genes to cells to organisms) and accelerate determination of targets, regulatory networks and integration of physiological responses within individuals and populations. The consortium includes molecular and developmental biologists, physiologists and human geneticists, and has access to major national and transnational data banks and resources. Nuclear receptor research is being revolutionised by the combination of technological advances with novel insights into signalling processes. CRESCENDO will ensure that European research in the field accelerates its momentum, fulfilling its potential to catalyse therapeutic innovation and to create substantial socio-economic benefit.

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Address

3 Rue Michel Ange
Paris

France

Participants (20)

Sort alphabetically

Expand all

KAROLINSKA INSTITUTET

Sweden

HELSINGIN YLIOPISTO

Finland

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFT E.V. REPRESENTED BY MAX PLANCK INSTITUTE OF PSYCHIATRY

Germany

UNIVERSITY OF MILAN

Italy

UNIVERSITY OF GENEVA

Switzerland

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

Spain

INSTITUTE OF MOLECULAR GENETICS - ACADEMY OF SCIENCES OF THE CZECH REPUBLIC - V.V.I

Czechia

UNIVERSITY OF OSLO

Norway

HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT, GMBH

Germany

STAZIONE ZOOLOGICA ANTON DOHRN

Italy

DEUTSCHES KREBSFORSCHUNGSZENTRUM

Germany

CENTRE EUROPÉEN DE RECHERCHE EN BIOLOGIE ET MÉDECINE - GROUPEMENT D'INTÉRÊT ECONOMIQUE

France

INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE

France

SERVIER RESEARCH INSTITUT

France

KARO BIO AB

Sweden

SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI

Italy

GENOME INSTITUTE OF SINGAPORE

Singapore

UNIVERSITÉ DE LAUSANNE

Switzerland

AXCENTUA PHARMACEUTICALS AB

Sweden

Project information

Grant agreement ID: 18652

  • Start date

    1 March 2006

  • End date

    31 August 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 13 503 522

  • EU contribution

    € 9 999 342

Coordinated by:

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France